gefitinib has been researched along with artesunic acid in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (artesunic acid) | Trials (artesunic acid) | Recent Studies (post-2010) (artesunic acid) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 2,089 | 443 | 1,182 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, D; Chen, D; Chen, LW; Li, H; Li, YW; Tan, B; Wang, WY; Xia, JN; Zhang, C; Zhu, GY | 1 |
1 other study(ies) available for gefitinib and artesunic acid
| Article | Year |
|---|---|
Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.
Topics: Animals; Artesunate; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Mice; Molecular Docking Simulation; Mutation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Transcription Factors | 2022 |